

I. Originalarbeiten

Harbrecht J, Hannoudi D, Teetz S, Tafel J, Feußner K, **Jaeger C (2012)** Endosonografisch gesteuerte transgastrisch-, transhepatische Cholangiodrainage (IEUC) bei einer Patientin mit lokal fortgeschrittenem Gallengangskarzinom. *Z Gastroenterol* 50: 30-33

Tafel J, Bürstell M, Leippert C, Benack E, Stelling A, **Jaeger C (2011)** Versorgungsrealität und Optimierung stationärer Diabetologie im Akutkrankenhaus der Schwerpunktversorgung: Untersuchung zur Prozessoptimierung, Qualitätssicherung und Kosteneffizienz. *Diabetologie* 6: 387-394

Winter S, Eckhard M, Bretzel RG, Bürstell M, Tafel J, **Jaeger C (2011)** Metabolic effects of insulin binding antibodies. *Diab Stoff Herz* 20: 369-372

Schmeiser T, Saar P, Jin D, Noethe M, Müller A, Soydan N, Hardt PD, **Jaeger C**, Distler O, Roeb E, Bretzel RG, Müller-Ladner U (**2011**) Profile of gastrointestinal involvement in patients with systemic sclerosis. *Rheumatol Int* (Epub 19.07.2011 ahead of print)

Pfleger C, Schloot NC, Brendel MD, Burkart V, Hogenkamp V, Bretzel RG, **Jaeger C**, Eckhard M (**2011**) Circulating cytokines are associated with human islet graft function in type 1 diabetes. *Clin Immunol* 138: 154-161

Schlosser M, Müller PW, Törn C, Bonifacio E, Bingley PJ; **Participating Laboratories (2010)** Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. *Diabetologia* 53: 2611-2620

Kempf K, Manzo G, Hanifi-Moghaddam P, Kappler S, Seissler J, **Jaeger C**, Boehm B, Roden M, Kolb H, Martin S, Schloot NC; Prodiab Study Group (**2009**) Effect of combined oral proteases and flavonoid treatment in subjects at risk of Type 1 diabetes. *Diabet Med* 26: 1309-1310

Hardt P, Ewald N, Bröckling K, Tanaka S, Endo T, Kloer HU, Bretzel RG, **Jaeger C**, Shimura H, Kobayashi T (**2008**) Distinct Autoantibodies Against Exocrine Pancreatic Antigens in European Patients with Type 1 Diabetes Mellitus and Non-alcoholic Chronic Pancreatitis. *JOP* 3: 683-689

Achenbach P, Bonifacio E, Williams AJ, Ziegler AG, Gale EA, Bingley PJ; **European Nicotinamide Diabetes Intervention Trial Group (2008)** Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. *Diabetologia* 51: 488-492

Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, **Participating Laboratories (2008)** Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. *Diabetologia* 51: 846-852

Jaeger C, Winter S, Eckhard M, Hardt P, Brendel MD, Bretzel (**2008**) Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules. *Acta Diabetologica* 45:191-194

Bingley PJ, Mahon JL, Gale EA; **European Nicotinamide Diabetes Intervention Trial Group (2008)** Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). *Diabetes Care* 31: 146-150

Seewi O, **Jaeger C**, Bretzel RG, Stockmann A, Schönau E (**2008**) Insulin binding to antibodies is a risk factor for inexplicable severe hypoglycaemia in children with type 1 diabetes mellitus. *Exp Clin Endocrinol Diabetes* 116: 293-297

Beck S, Fühlhuber V, Krasenbrink I, Tschernatsch M, Kneifel N, Kirsten A, **Jaeger C**, Kaps M, Preissner KT, Lang B, Rostasy K, Blaes F (2007) IgG subclass distribution of autoantibodies in pediatric opsoclonus-myooclonus syndrome. *J Neuroimmunol* 185: 145-149

Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, Guenter E, Ell C (2006) Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: Clinical presentation, endoscopic findings, treatment, and follow-up. *Endoscopy* 38: 730-734

Friedrich-Rust M, **Jaeger C**, Gossner L, May A, Guenter E, Stolte M, Ell C (2006) Early duodenal Adenocarcinoma arising in gastric metaplasia treated by endoscopic resection (Case Report). *Z Gastroenterol* 44: 323-328

Bingley PJ, Gale EA; The European Nicotinamide Diabetes Intervention Trial (**ENDIT**) Group (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. *Diabetologia* 49: 881-890

Jaeger C, May A, Gossner L, Rabenstein T, Schroeder M, Stolte M, Ell C (2005) Successful endoscopic resection of an esophageal metastasis from a preceding squamous-cell tonsillar carcinoma (Case Report). *Endoscopy* 37: 1023-1026

Jaeger C, Eckhard M, Brendel MD, Bretzel RG (2004) Diagnostic algorithm and management of immune mediated complications associated with subcutaneous insulin therapy. *Exp Clin Endocrinol Diabetes* 112: 416-421

Eckhard M, Brandhorst D, Winter D, **Jaeger C**, Jahr H, Bretzel RG, Brendel MD (2004) The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. *Transplant Proc* 36: 1528-1531

Gale EA, Bingley PJ, Emmet CL, Collier T; European Nicotinamide Diabetes Intervention Trial (**ENDIT**) Group (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. *Lancet* 363: 925-931

Hardt PD, Hauenschild A, **Jaeger C**, Teichmann J, Bretzel RG, Kloer HU, S2453112/S2453113 Study Group (2003) High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a prospective multicenter study. *Dig Dis Sci* 48: 1688-1692

Hardt PD, Hauenschild A, Nalop J, Marzeion AM, **Jaeger C**, Teichmann J, Bretzel RG, Hollenhorst M, Kloer HU, S2453112/S2453113 Study Group (2003) High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1.021 diabetic patients. *Pancreatology* 3: 395-402

The European Nicotinamide Diabetes Intervention (**ENDIT**) Group (2003) Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). *Diabetologia* 46: 339-346

Jaeger C, Hatziagelaki E, Petzoldt R, Bretzel RG (2001) Comparative analysis of organ-specific autoantibodies and celiac disease-associated antibodies in type 1 diabetic patients, their first degree relatives and healthy control subjects. *Diabetes Care* 24: 27-32

Ademmer K, Beutel M, Bretzel R, **Jaeger C**, Reimer C (2001) Suicidal ideation with IFN- α and Ribaverin in a patient with hepatitis C (Case Report). *Psychosomatics* 42: 365-367

Jaeger C, Hatziagelaki E, Stroedter A, Becker F, Scherer S, Petzoldt R, Federlin K, Bretzel RG (1999) The Giessen-Bad Oeynhausen family study: Improved prediction of type I diabetes in a low

incidence population of relatives using combinations of autoantibodies in a dual step model. *Exp Clin Endocrinol Diabetes* 107: 496-505

Hatziagelaki E, **Jaeger C**, Petzoldt R, Seissler J, Scherbaum WA, Federlin K, Bretzel RG (1999) The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk for type 1 diabetes mellitus. *Horm Metab Res* 31: 564-569

Jaeger C, Hering BJ, Hatziagelaki E, Federlin K, Bretzel RG (1999) Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. *J Mol Med* 77: 45-48

Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H and the **DENIS Group** (1998) The Deutsche Nicotinamide Intervention Study: An Attempt to Prevent Type 1 Diabetes. *Diabetes* 47: 980-984

Jaeger C, Brendel MD, Hering BJ, Eckhard M, Federlin K, Bretzel RG (1998) IA-2 autoantibodies are only positive in association with GAD 65 and islet cell antibodies in islet transplanted IDDM patients. *Transplantation Proceedings* 30: 659-660

Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG (1997) Progressive islet graft failure occurs significantly earlier in autoantibody positive than in autoantibody negative IDDM recipients of intrahepatic islet allografts. *Diabetes* 46: 1907-1910

Jaeger C, Allendörfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzel RG (1997) Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual betacell function, neuropathy or HLA-DR status. *Horm Metab Res* 29: 510-515

Hatziagelaki E, **Jaeger C**, Mäser E, Bretzel RG, Federlin K (1996) GAD 65 antibody positivity in adult-onset diabetic patients is associated with early progression to clinical insulin dependency. *Acta Diabetologica* 33: 291-294

Jaeger C, Hering BJ, Dyrberg T, Federlin K, Bretzel RG (1996) Islet cell antibodies and GAD 65 antibodies in IDDM patients undergoing kidney and islet after kidney transplantation. *Transplantation* 62: 424-426

Jaeger C, Wöhrle M, Federlin K, Bretzel RG (1995) Pancreatic islet xenografts at two different transplantation sites (renal subcapsular vs. intraportal): Comparison of graft survival and morphology. *Exp Clin Endocrinol Diabetes* 103, Suppl 2: 123-128

Jaeger C, Wöhrle M, Bretzel RG, Federlin K (1994) Effect of transplantation site and culture pretreatment on islet xenograft survival (rat to mouse) in experimental diabetes without immunosuppression of the host. *Acta Diabetol* 41: 193-197

II. Übersichten

Tafel J, Bürstell M, Leippert C, Benack E, Stelling A, **Jaeger C** (2011) Diabetes Management in der Klinik: Nutzen, Kosten, Erlöse. *Der Diabetologe* 7: 472-479

Jaeger C, Bretzel RG (2006) Diagnostik und Therapie immunologischer Komplikationen bei Insulintherapie in der klinischen Praxis. *Diabetologie* 1: 114-121

Brendel MD, Eckhard M, Brandhorst D, Brandhorst H, Winter D, **Jaeger C**, Ziegler A, Iken M, Shen H, Weimer R, Rau W, Padberg W, Bretzel RG (2003) Inselzelltransplantation – aktueller Stand und Perspektiven. *Diabetes und Stoffwechsel* 12: 239-252

Harsch I, **Jaeger C (2002)** Inhalative und orale Insuline. Diabetes und Stoffwechsel 11: 254-255

Jaeger C, Brendel MD, Eckhard M, Bretzel RG **(2000)** Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes 108: 328-333